Literature DB >> 11093807

Monoclonal antibody DS6 detects a tumor-associated sialoglycotope expressed on human serous ovarian carcinomas.

K P Kearse1, N L Smith, D A Semer, L Eagles, J L Finley, S Kazmierczak, C J Kovacs, A A Rodriguez, A E Kellogg-Wennerberg.   

Abstract

A newly developed murine monoclonal antibody, DS6, immunohistochemically reacts with an antigen, CA6, that is expressed by human serous ovarian carcinomas but not by normal ovarian surface epithelium or mesothelium. CA6 has a limited distribution in normal adult tissues and is most characteristically detected in fallopian tube epithelium, inner urothelium and type 2 pneumocytes. Pre-treatment of tissue sections with either periodic acid or neuraminidase from Vibrio cholerae abolishes immunoreactivity with DS6, indicating that CA6 is a neuraminidase-sensitive and periodic acid-sensitive sialic acid glycoconjugate ("sialoglycotope"). SDS-PAGE of OVCAR5 cell lysates has revealed that the CA6 epitope is expressed on an 80 kDa non-disulfide-linked glycoprotein containing N-linked oligosaccharides. Two-dimensional non-equilibrium pH gradient gel electrophoresis indicates an isoelectric point of approximately 6.2 to 6.5. Comparison of the immunohistochemical distribution of CA6 in human serous ovarian adenocarcinomas has revealed similarities to that of CA125; however, distinct differences and some complementarity of antigen expression were revealed by double-label, 2-color immunohistochemical studies. The DS6-detected CA6 antigen appears to be distinct from other well-characterized tumor-associated antigens, including MUC1, CA125 and the histo-blood group-related antigens sLea, sLex and sTn. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11093807     DOI: 10.1002/1097-0215(20001215)88:6<866::aid-ijc5>3.0.co;2-6

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

Review 1.  Antibody-drug conjugates and other nanomedicines: the frontier of gynaecological cancer treatment.

Authors:  David Howard; Jetzabel Garcia-Parra; Gareth D Healey; Cynthia Amakiri; Lavinia Margarit; Lewis W Francis; Deyarina Gonzalez; R Steven Conlan
Journal:  Interface Focus       Date:  2016-12-06       Impact factor: 3.906

2.  Development and Validation of an Immuno-PET Tracer as a Companion Diagnostic Agent for Antibody-Drug Conjugate Therapy to Target the CA6 Epitope.

Authors:  Ohad Ilovich; Arutselvan Natarajan; Sharon Hori; Ataya Sathirachinda; Richard Kimura; Ananth Srinivasan; Mathias Gebauer; Jochen Kruip; Ingo Focken; Christian Lange; Chantal Carrez; Ingrid Sassoon; Veronique Blanc; Susanta K Sarkar; Sanjiv S Gambhir
Journal:  Radiology       Date:  2015-02-27       Impact factor: 11.105

3.  Identification of Prognostic and Susceptibility Markers in Chronic Myeloid Leukemia Using Next Generation Sequencing.

Authors:  Yogender Shokeen; Neeta Raj Sharma; Abhishek Vats; Vibha Taneja; Sachin Minhas; Mayank Jauhri; Satish Sankaran; Shyam Aggarwal
Journal:  Ethiop J Health Sci       Date:  2018-03

Review 4.  Potential of Anti-MUC1 Antibodies as a Targeted Therapy for Gastrointestinal Cancers.

Authors:  Mukulika Bose; Pinku Mukherjee
Journal:  Vaccines (Basel)       Date:  2020-11-05

Review 5.  Advances in MUC1-Mediated Breast Cancer Immunotherapy.

Authors:  Zhifeng Li; Dazhuang Yang; Ting Guo; Mei Lin
Journal:  Biomolecules       Date:  2022-07-06

6.  Two Patient Studies of a Companion Diagnostic Immuno-Positron Emission Tomography (PET) Tracer for Measuring Human CA6 Expression in Cancer for Antibody Drug Conjugate (ADC) Therapy.

Authors:  Arutselvan Natarajan; Shyam M Srinivas; Carmen Azevedo; Lacey Greene; Anne-Laure Bauchet; Erwan Jouannot; Anne-Sophie Lacoste-Bourgeacq; Isabelle Guizon; Patrick Cohen; Anne-Laure Naneix; Ohad Ilovich; Jordan Cisneros; Krithika Rupanarayan; Frederick T Chin; Andrei Iagaru; Frederick M Dirbas; Amer Karam; Sanjiv S Gambhir
Journal:  Mol Imaging       Date:  2020 Jan-Dec       Impact factor: 4.488

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.